169547-67-5 Usage
Uses
Used in Organic Synthesis:
3-(4-(Bromomethyl)phenyl)isoxazole is used as a building block in organic synthesis for the creation of various pharmaceuticals and other biologically active compounds. Its unique structure allows it to be a versatile component in the development of new molecules with potential therapeutic properties.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(4-(Bromomethyl)phenyl)isoxazole is utilized as a key intermediate for the synthesis of drugs. Its presence in a molecule can influence the pharmacokinetics and pharmacodynamics, contributing to the overall effectiveness and safety of the final drug product.
Used as a Reagent in Chemical Reactions:
3-(4-(Bromomethyl)phenyl)isoxazole also serves as a reagent in chemical reactions, particularly for the formation of chemical bonds in heterocyclic chemistry. Its reactivity and stability make it a valuable tool for researchers working on the synthesis of complex organic molecules.
Used in the Development of New Drugs and Materials:
3-(4-(BroMoMethyl)phenyl)isoxazole has potential applications in the development of new drugs and materials, thanks to its ability to be incorporated into a wide range of chemical structures. Its presence in a molecule can enhance properties such as solubility, stability, and bioavailability, which are crucial for the success of a drug candidate or a new material in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 169547-67-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,9,5,4 and 7 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 169547-67:
(8*1)+(7*6)+(6*9)+(5*5)+(4*4)+(3*7)+(2*6)+(1*7)=185
185 % 10 = 5
So 169547-67-5 is a valid CAS Registry Number.
169547-67-5Relevant academic research and scientific papers
Azabicyclic heterocycles as cannabinoid receptor modulators
-
Page/Page column 84, (2008/06/13)
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R6, R7, m and n are described herein.
